A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-01

Study Completion Date

2025-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A pilot study to assess the safety and tolerability of an orally administered natural product derived from hops, called xanthohumol, in humans with Crohn's Disease, in order to identify a biological signature of xanthohumol exposure, and to characterize the role of xanthohumol metabolism by intestinal microorganisms in that signature within adults with Crohn's Disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase II Study of HMPL-004 in Subjects With Crohn's Disease

NCT00655733

Crohn's Disease

COMPLETED PHASE2

CP-461 for the Treatment of Crohn's Disease

NCT00042055

Crohn's Disease

COMPLETED PHASE2

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

NCT01203631

Inflammation Crohn's Disease

COMPLETED PHASE2

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

NCT06450197

Moderate to Severe Crohn's Disease

RECRUITING PHASE2

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

NCT00032799

Crohn's Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a double-masked, placebo controlled, randomized clinical trial of xanthohumol, which is a constituent of hops (Humulus lupulus). Hops and its constituents have a long history of use for a variety of conditions. However, knowledge is limited regarding the measurable biological markers of human exposure, and the role of xanthohumol metabolism by microorganisms present in the gut, particularly in individuals with gut pathologies such as Crohn's Disease. This information is necessary for the development of xanthohumol as a potential therapeutic intervention in such conditions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants will be randomized to receive either encapsulated xanthohumol in a rice protein vehicle, or an identical capsule containing vehicle alone.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Randomization will occur in up to 8 blocks of 4 based on biological sex. Initial randomization series will be generated using readily available random sequence generators designed to do so. A series of sequential envelopes will be generated, each containing the allocation for one participant. Envelopes will be opaque and signed across the seal. The randomization "code" will be kept in a sealed envelope with a signature across the label and dated the day of creation. Study product and comparator (placebo) will be compounded and placed in identical opaque capsules outside the institution.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Xanthohumol

Participants will take capsules containing 24 mg of xanthohumol in a rice protein vehicle by mouth once daily with the first daily meal.

Group Type EXPERIMENTAL

Xanthohumol

Intervention Type DRUG

The xanthohumol supplement will be administered in a capsule and taken orally.

Placebo

Participants will receive capsules filled with a rice protein vehicle by mouth once daily with the first daily meal.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

The placebo will be administered in a capsule and taken orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xanthohumol

The xanthohumol supplement will be administered in a capsule and taken orally.

Intervention Type DRUG

Placebo

The placebo will be administered in a capsule and taken orally.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults 21-50 years of age
* Active Crohn's disease not in remission based on a CDAI score \>150
* Willing to take isolated Xanthohumol as a dietary supplement for 8 weeks
* Willing to have blood drawn bi-weekly and fast for 10-12 hours before blood draws
* Willing and able to collect bi-weekly stool samples at home
* Willing and able to collect a 24-hour urine sample before each study visit
* Able to speak, read and understand English
* Must be able to provide written informed consent
* Non-smokers (including tobacco and Cannabis products, combusted or vaporized)
* For individuals of child-bearing potential, willingness to use an intrauterine device (IUD) or two other concurrent forms of birth control (e.g., 2 of the following categories: condoms, spermicide-containing gels, films or sponges; and/or vaginal rings) to prevent pregnancy while enrolled

Exclusion Criteria

* Highly variable dosing of anti-inflammatory medications (dose changes more than 1x per week)
* Currently or recent (within last 14 days) taking any dietary supplements containing xanthohumol, flavonoids, or other known "anti-inflammatories" including: curcumin, turmeric, fenugreek, hops, rosemary, ginger, white willow, devil's claw, fish oil (doses\>1 g/day), or quercetin. Candidates will be given the option to "wash out" for 14 days and re-contact the study team.
* Consumption of more than 1 beer per day.
* Currently receiving intravenous nutrition support therapy (or within the last 14 days)
* Currently taking anti-coagulant or anti-platelet prescription medications (or they were taken within the last 14 days)
* Currently taking antibiotic, antiparasitic, or antifungal medications orally or intravenously (or they were taken within the last 14 days)
* Initiation of or changes to supplements or medications within 14 days prior to screening.
* Initiation of or changes to an exercise regimen within 14 days prior to screening.
* Initiation of or changes to a food plan within 14 days prior to screening.
* Current involvement or within 14 days prior to screening of a significant diet or weight loss program (such as NutriSystem, Jenny Craig, Atkin's or other low-carb diet programs) or very low-calorie liquid diet programs (such as Optifast, Medifast, and/or HMR)
* Hospitalization (for any reason other than a scheduled medical procedure) within 3 months prior to screening
* Gastrointestinal surgery within 3 months prior to screening
* Malignancy within the last 5 years (with the exception of basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix)
* Women who are lactating, pregnant or planning pregnancy within the next four months
* Typical intake of more than 2 alcohol-containing beverages per day, more than 14 per week, or more than 4 in any single day within the past 14 days.
* Smoking tobacco or nicotine products (combusted or vaporized)
* Use of illicit drugs/substances (such as but not limited to cocaine, phencyclidine (PCP), and methamphetamine) within 14 days of screening
* Use of inhaled or ingested Cannabis products, including Cannabidiol (CBD)
* Currently participating in another interventional research study, or participated in another interventional research study within 14 days of screening
* Do not have an active primary care provider or specialist (i.e., gastroenterologist) managing their CD

Minimum Eligible Age

21 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No